Poliomyelitis is a highly infectious viral disease that mainly affects children under 5 years old. While most infections cause no symptoms, it can sometimes lead to paralysis or death. There is no cure for polio, but vaccination provides lifelong protection. Global polio cases have decreased over 99% since 1988 due to vaccination efforts. Nepal eliminated indigenous polio in 2000 and participates in regional certification efforts. The national immunization program aims to provide equitable access to vaccines to prevent diseases like polio.
Hi everyone! I am Bidisha Goswami , an Integrated Marketing Communications Masters student at the Florida State University.This video is my study on the ICT approach for polio eradication in India.
This dangerous disease was eradicated from the entire nation after quite a struggle using various media campaigns in various forms.Now , we are proud to have the polio-free certificate from World Health Organization.This is at least one step closer to the massive steps taken to eradicate polio from the entire world.
Hi everyone! I am Bidisha Goswami , an Integrated Marketing Communications Masters student at the Florida State University.This video is my study on the ICT approach for polio eradication in India.
This dangerous disease was eradicated from the entire nation after quite a struggle using various media campaigns in various forms.Now , we are proud to have the polio-free certificate from World Health Organization.This is at least one step closer to the massive steps taken to eradicate polio from the entire world.
Past and future of eradication and elimination of different diseases. How to plan for elimination and eradication. What are the diseases can be eliminated? OPV to IPV shift!
The PPT gives overview of PEI, global updates on PEI, Polio end game strategy and eradication timelines, polio legacy and link with Health Systems strengthening and relevant health programes etc. The PPT was presented at National Annual Review Meeting held for 2 days in Mussoorie for Core Group of Polio Project (CGPP) -a USAID funded polio eradication initiatives. ADRA India is one of the lead implementing agency for CGPP since 2004 and it has worked for nearly 15 years in polio across states in India.
Universal Immunization Program is a vaccination program launched by the Government of India in 1985.
It became a part of Child Survival and Safe Motherhood Program in 1992 and is currently one of the key areas under National Rural Health Mission(NRHM) since 2005.
Program consists of vaccination for 12 diseases -
Tuberculosis
Diphtheria
Pertussis
Tetanus,
Poliomyelitis,
Measles,
Hepatitis B,
Diarrhea,
Japanese-Encephalitis,
Rubella,
Pneumonia
Pneumococcal diseases
Past and future of eradication and elimination of different diseases. How to plan for elimination and eradication. What are the diseases can be eliminated? OPV to IPV shift!
The PPT gives overview of PEI, global updates on PEI, Polio end game strategy and eradication timelines, polio legacy and link with Health Systems strengthening and relevant health programes etc. The PPT was presented at National Annual Review Meeting held for 2 days in Mussoorie for Core Group of Polio Project (CGPP) -a USAID funded polio eradication initiatives. ADRA India is one of the lead implementing agency for CGPP since 2004 and it has worked for nearly 15 years in polio across states in India.
Universal Immunization Program is a vaccination program launched by the Government of India in 1985.
It became a part of Child Survival and Safe Motherhood Program in 1992 and is currently one of the key areas under National Rural Health Mission(NRHM) since 2005.
Program consists of vaccination for 12 diseases -
Tuberculosis
Diphtheria
Pertussis
Tetanus,
Poliomyelitis,
Measles,
Hepatitis B,
Diarrhea,
Japanese-Encephalitis,
Rubella,
Pneumonia
Pneumococcal diseases
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
2. Poliomylitis
• Poliomyelitis (polio) is a highly infectious viral disease, which mainly
affects young children.
• The poliovirus can easily be imported into a polio-free country and
can spread rapidly amongst unimmunized populations
• There is no cure for polio, it can only be prevented. Polio vaccine,
given multiple times, can protect a child for life.
A man with a smaller right leg due to poliomyelitis
3. • Polio (or poliomyelitis) is a disabling and life-
threatening disease caused by poliovirus,
which can infect a person’s spinal cord, leading
to paralysis.
• Most people infected with poliovirus have no
symptoms, and many recover without
complications. Some people will experience
sore throat, fever, tiredness, nausea,
headache, or stomach pain.
4. Poliomylitis
Causetive organism : poliovirus. : This group
of RNA viruses.
incubation period, is usually 6 to 20 days,
with a maximum range of 3 to 35 days
Mode of disease transmission
The virus is transmitted by person-to-person
spread mainly through the faecal-oral route
7. History
polio epidemics were unknown before the 20th century, the
disease has caused paralysis and death for much of human history.
Over millennia, polio survived quietly as an endemic pathogen until
the 1900s when major epidemics began to occur in Europe.
Soon after, widespread epidemics appeared in the United States.
By 1910, frequent epidemics became regular events throughout the
developed world primarily in cities during the summer months. At its
peak in the 1940s and 1950s, polio would paralyze or kill over half a
million people worldwide every year.
Perhaps the earliest recorded case of poliomyelitis is that of Sir
Walter Scott. In 1773 Scott was said to have developed "a
severe teething fever which deprived him of the power of his right leg
8. Two vaccines are used throughout the world
to combat polio. The first was developed
by Jonas Salk.
First tested in 1952 using the HeLa cell, and
announced to the world by Salk on April 12,
1955.
The Salk vaccine, or inactivated poliovirus
vaccine (IPV), consists of an injected dose of
killed poliovirus. In 1954, the vaccine was
tested for its ability to prevent polio
9. Epidemiology
• Wild poliovirus cases have decreased by over
99% since 1988, from an estimated 350 000
cases in more than 125 endemic countries
then, to 33 reported cases in 2018.
• Of the 3 strains of wild poliovirus (type 1, type
2, and type 3), wild poliovirus type 2 was
eradicated in 1999 and no case of wild
poliovirus type 3 has been found since the last
reported case in Nigeria in November 2012.
10. • Polio does still exist, although polio cases have
decreased by over 99% since 1988, from an
estimated more than 350 000 cases to 22
reported cases in 2017.
• This reduction is the result of the global effort
to eradicate the disease. Today, only 3
countries in the world have never stopped
transmission of polio Pakistan, Afghanistan
and Nigeria).
11. Key fact
Polio (poliomyelitis) mainly affects children under 5 years of age.
1 in 200 infections leads to irreversible paralysis. Among those
paralysed, 5% to 10% die when their breathing muscles become
immobilized.
Cases due to wild poliovirus have decreased by over 99% since
1988, from an estimated 350 000 cases then, to 33 reported cases
in 2018.
As long as a single child remains infected, children in all countries
are at risk of contracting polio.
the global effort has expanded capacities by building effective
surveillance and immunization systems.
An estimated 1.5 million childhood deaths have been prevented,
through the systematic administration of vitamin A during polio
immunization activities.
12. In Nepal
• Nepal eliminated indigenous polio in 2000 and
controlled outbreaks caused by polio importations
between 2005 and 2010.
• The country participated in the certification of wild
poliovirus elimination in the World Health Organization
(WHO) South-East Asia Region in 2014.
• Nepal’s polio eradication programme, created in 1998,
is funded by the Global Polio Eradication Initiative and
is affiliated with WHO’s Nepal country office.
13. In nepal
Comprehensive Multi-Year Plan for
Immunization (cMYP)
• The comprehensive Multi-year Plan for
Immunization (cMYP) 2012 - 16 ended in
2016 and new cMYP 2017-21 is in place. The
cMYP 2017-2021 provides a plan for five
years to achieve immunization related
• goals of the country.
14. • Vision
• Nepal: a country free of vaccine-preventable
diseases.
• Mission
To provide every child and mother high-quality,
safe and affordable vaccines and immunization
services from the National Immunization Program
in an equitable manner.
• Goal
Reduction of morbidity, mortality and disability
associated with vaccine preventable diseases.
19. P3CE of polio virus
1 Heath promotion
Personal hygiene
Environment sanitation
Proper utilization of toilet
Breast feeding
2 Prevention
Don’t touch ill people people are in healthy stage
Use mask
Hand wash
3 protection
Immunization of polio vaccine
20. 4 Control of Epidemic actions
Controlling the reservoir
1. Early diagnosis
2. Notification
3. Epidemiological investigations
4. Isolation
5. Quarantine
6 Interruption of transmission
21. 5 Encourage for early diagnosis and
compliance treatment
• Early diagnosis generally increases the
chances for successful treatment by focusing
on detecting symptomatic patients as early as
possible. Delays in accessing care are
common with late-stage presentation,
particularly in lower resource settings and
vulnerable populations.
23. Reference
1 Annual report . government of Nepal ministry of heath and
population . Department of heath service 2074-2075
2 World heath organization . Accessed April 19, 2020
3 Central for disease control and prevention Accessed April 19, 2020
4 Collier, William Douglas . A history of English literature, in a series of
biographical sketches. 1872.
5 Dr maheshori jaykumari . epidemiology of Polio.
6 Wikipedia, the free encyclopedia (Accessed: April 19, 2020
7 Bahl S, Kumar R, Menabde N, Thapa A, McFarland J, Swezy V, et
al. Polio-free certification and lessons learned–South-East Asia
region, March 2014.